The Evolving Treatment Paradigm in Multiple Myeloma: Recent Updates - Episode 12

Bispecifics in Multiple Myeloma: Dosing and Transition of Care

, , , ,

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?
    EP. 2: NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy
    EP. 3: Induction Therapy Regimens for Transplant-Eligible NDMM
    EP. 4: Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma
    EP. 5: Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
    EP. 6: Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma
    EP. 7: Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma
    EP. 8: Patient Scenario: Treatment Options in MM at First Relapse
    EP. 9: Factors in Selecting Therapy at First Relapse in Multiple Myeloma
    EP. 10: Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy
    EP. 11: Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment
    Now Viewing
    EP. 12: Bispecifics in Multiple Myeloma: Dosing and Transition of Care
    EP. 13: Combination Strategies With Bispecifics in Multiple Myeloma
    EP. 14: Bispecifics in Multiple Myeloma: Adverse Event Management
    EP. 15: CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond
    EP. 16: Multiple Myeloma: Unmet Needs and Future Directions in Care
    x